346 related articles for article (PubMed ID: 17938126)
41. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
42. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial.
Ellis SG; O'Shaughnessy CD; Martin SL; Kent K; McGarry T; Turco MA; Kereiakes DJ; Popma JJ; Friedman M; Koglin J; Stone GW;
Eur Heart J; 2008 Jul; 29(13):1625-34. PubMed ID: 18556716
[TBL] [Abstract][Full Text] [Related]
43. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years.
Ellis SG; Colombo A; Grube E; Popma J; Koglin J; Dawkins KD; Stone GW
J Am Coll Cardiol; 2007 Mar; 49(10):1043-51. PubMed ID: 17349883
[TBL] [Abstract][Full Text] [Related]
44. Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries.
Bonello L; De Labriolle A; Lemesle G; Roy P; Steinberg DH; Slottow TL; Xue Z; Torguson R; Kaneshige K; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
Am J Cardiol; 2009 Feb; 103(4):496-500. PubMed ID: 19195509
[TBL] [Abstract][Full Text] [Related]
45. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
46. Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program.
Lasala JM; Cox DA; Morris DL; Breall JA; Mahoney PD; Horwitz PA; Shaw D; Hood KL; Mandinov L; Dawkins KD
Am J Cardiol; 2009 Jun; 103(12):1663-71. PubMed ID: 19539073
[TBL] [Abstract][Full Text] [Related]
47. [Short and long-term therapeutic effects of rapamycin-eluting stent and paclitaxel-eluting stent in treatment of coronary disease with complicated lesions].
Chen JL; Gao RL; Yang YJ; Qiao SB; Qin XW; Yao M; Liu HB; Xu B; Wu YJ; Yuan JQ; Chen J; Dai J; You SJ; Ma WH
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(31):2183-6. PubMed ID: 16321180
[TBL] [Abstract][Full Text] [Related]
48. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts.
Gioia G; Benassi A; Mohendra R; Chowdhury K; Masood I; Matthai W
Catheter Cardiovasc Interv; 2008 Jul; 72(1):13-20. PubMed ID: 18561143
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
[TBL] [Abstract][Full Text] [Related]
50. Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS II.
Silber S; Hamburger J; Grube E; Pfisterer M; Belardi J; Webb J; Zmudka K; Nienaber C; Hauptman K; Rutsch W; Dawkins K; Drzewiecki J; Koglin J; Colombo A
Herz; 2004 Mar; 29(2):171-80. PubMed ID: 15057438
[TBL] [Abstract][Full Text] [Related]
51. Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry).
Roy P; Bonello L; de Labriolle A; Okabe T; Pinto Slottow TL; Steinberg DH; Torguson R; Smith K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
Am J Cardiol; 2008 Aug; 102(3):292-7. PubMed ID: 18638589
[TBL] [Abstract][Full Text] [Related]
52. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial.
Kelbaek H; Kløvgaard L; Helqvist S; Lassen JF; Krusell LR; Engstrøm T; Bøtker HE; Jørgensen E; Saunamäki K; Aljabbari S; Thayssen P; Galløe A; Jensen GV; Thuesen L
J Am Coll Cardiol; 2008 May; 51(21):2011-6. PubMed ID: 18498953
[TBL] [Abstract][Full Text] [Related]
53. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
Qasim A; Cosgrave J; Latib A; Colombo A
Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
[TBL] [Abstract][Full Text] [Related]
54. Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions.
Lee CW; Park DW; Seung KB; Kim PJ; Park HJ; Kim WJ; Lee JY; Kang SJ; Lee SH; Kim YH; Park SW; Park SJ
Am J Cardiol; 2011 Apr; 107(7):990-4. PubMed ID: 21296317
[TBL] [Abstract][Full Text] [Related]
55. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A;
Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155
[TBL] [Abstract][Full Text] [Related]
56. Drug-eluting stents: clinical experiences and perspectives.
Grube E; Gerckens U; Buellesfeld L
Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
[TBL] [Abstract][Full Text] [Related]
57. Treatment of left main coronary trifurcation lesions with the paclitaxel drug-eluting stent: mid-term outcomes from a tertiary medical center.
Shammas NW; Shammas GA; Jerin M; Parikh A; Coin K; Dippel E; Sharis P; Robken J
J Invasive Cardiol; 2009 Jul; 21(7):321-5. PubMed ID: 19571341
[TBL] [Abstract][Full Text] [Related]
58. Randomized comparison between intracoronary beta-radiation brachytherapy and implantation of paclitaxel-eluting stents for the treatment of diffuse in-stent restenosis.
Schukro C; Syeda B; Kirisits C; Schmid R; Pichler P; Pokrajac B; Lang I; Pötter R; Glogar D
Radiother Oncol; 2007 Jan; 82(1):18-23. PubMed ID: 16971011
[TBL] [Abstract][Full Text] [Related]
59. Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry.
Daemen J; Kukreja N; van Twisk PH; Onuma Y; de Jaegere PP; van Domburg R; Serruys PW
Am J Cardiol; 2008 Apr; 101(8):1105-11. PubMed ID: 18394442
[TBL] [Abstract][Full Text] [Related]
60. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions.
Iofina E; Langenberg R; Blindt R; Kühl H; Kelm M; Hoffmann R
Am J Cardiol; 2006 Oct; 98(8):1022-7. PubMed ID: 17027564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
